
    
      OBJECTIVES: I. Assess the antitumor activity of aminocamptothecin (9-AC) administered by
      72-hour infusion in patients with advanced cutaneous T-cell lymphoma. II. Assess the toxic
      effects of 9-AC administered on this schedule.

      OUTLINE: Single-Agent Chemotherapy. Aminocamptothecin, 9-AC, NSC-603071.

      PROJECTED ACCRUAL: A total of 30 patients will be accrued; if no more than 1 response is seen
      in the first 15 patients, the study will close. Probable duration of study is 18 months.
    
  